Despite we have already demonstrated, in other preclinical models of AD, that PEA exerts its pharmacological effects through the peroxisome proliferator-activated receptors alpha (PPARα) involvement11–13,47, other molecular targets should be taken into account, including PPARγ, transient receptor potential vanilloid type-1 channel, orphan G-protein-coupled receptor 55, and the so-called entourage effect on the endocannabinoid system19. The gene discussed is PPARG; the disease is Alzheimer disease.